Evidence map›Paper›PMID 35325259›Full record

ArticleDiabetologia2022

Opposing roles of the entero-pancreatic hormone urocortin-3 in glucose metabolism in rats.

Kaare V Grunddal, Samuel A J Trammell, Cecilie Bæch-Laursen, Daniel B Andersen, Stella F S Xu, Helle Andersen, Matthew P Gillum, Seyed M Ghiasi, Ivana Novak, Björn Tyrberg and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Urocortin 3 function in glucose metabolism.Nature reviews. Endocrinology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Kaare V GrunddalDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Samuel A J TrammellDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Cecilie Bæch-LaursenDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Daniel B AndersenDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Stella F S XuDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Helle AndersenGlobal Obesity and Liver Disease Research, Novo Nordisk, Måløv, Denmark.
Matthew P GillumNovo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Seyed M GhiasiDepartment of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Ivana NovakDepartment of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Björn TyrbergDepartment of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Chien LiGlobal Obesity and Liver Disease Research, Novo Nordisk, Seattle, WA, USA.
Mette M RosenkildeDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Bolette HartmannDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark.
Jens J HolstDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark. jjholst@sund.ku.dk.
Rune E KuhreDepartment of Biomedical Sciences, Faculty of Health and Medical, Sciences, University of Copenhagen, Copenhagen, Denmark. kuhre@sund.ku.dk.
University of Copenhagen · DKNovo Nordisk Foundation · DKImperial College London · GBNovo Nordisk (Denmark) · DKNovo Nordisk (United States) · USUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aim/hypothesisUrocortin-3 (UCN3) is a glucoregulatory peptide produced in the gut and pancreatic islets. The aim of this study was to clarify the acute effects of UCN3 on glucose regulation following an oral glucose challenge and to investigate the mechanisms involved.

methodsWe studied the effect of UCN3 on blood glucose, gastric emptying, glucose absorption and secretion of gut and pancreatic hormones in male rats. To supplement these physiological studies, we mapped the expression of UCN3 and the UCN3-sensitive receptor, type 2 corticotropin-releasing factor receptor (CRHR2), by means of fluorescence in situ hybridisation and by gene expression analysis.

resultsIn rats, s.c. administration of UCN3 strongly inhibited gastric emptying and glucose absorption after oral administration of glucose. Direct inhibition of gastrointestinal motility may be responsible because UCN3's cognate receptor, CRHR2, was detected in gastric submucosal plexus and in interstitial cells of Cajal. Despite inhibited glucose absorption, post-challenge blood glucose levels matched those of rats given vehicle in the low-dose UCN3 group, because UCN3 concomitantly inhibited insulin secretion. Higher UCN3 doses did not further inhibit gastric emptying, but the insulin inhibition progressed resulting in elevated post-challenge glucose and lipolysis. Incretin hormones and somatostatin (SST) secretion from isolated perfused rat small intestine was unaffected by UCN3 infusion; however, UCN3 infusion stimulated secretion of somatostatin from delta cells in the isolated perfused rat pancreas which, unlike alpha cells and beta cells, expressed Crhr2. Conversely, acute antagonism of CRHR2 signalling increased insulin secretion by reducing SST signalling. Consistent with these observations, acute drug-induced inhibition of CRHR2 signalling improved glucose tolerance in rats to a similar degree as administration of glucagon-like peptide-1. UCN3 also powerfully inhibited glucagon secretion from isolated perfused rat pancreas (perfused with 3.5 mmol/l glucose) in a SST-dependent manner, suggesting that UCN3 may be involved in glucose-induced inhibition of glucagon secretion. CONCLUSIONS/

interpretationOur combined data indicate that UCN3 is an important glucoregulatory hormone that acts through regulation of gastrointestinal and pancreatic functions.

Indexed as

Islets of LangerhansUrocortinsAnimalsBlood GlucoseGlucagonGlucoseInsulinMaleRatsSomatostatinBlood GlucoseGlucagonGlucoseInsulinSomatostatinUrocortinsBlood glucoseCorticotropin-releasing factor receptor 2Gastric emptyingGlucose absorptionInsulin secretionSomatostatinUrocortin-3

Identifiers

PMID35325259
PMCPMC9076751
OpenAlexW4221069978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.